Trial
NCT01740401
CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma
Phase IITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
Icahn School of Medicine at Mount Sinai
Collaborators
Bristol-Myers Squibb
Condition
Melanoma
Intervention
Cyclophosphamide
Why stopped
Primary Endpoint not met
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2017-12-06